Other languages Imunon, Inc.

Equities

IMNN

US15117N6022

Delayed Nasdaq Other stock markets 12:10:24 2024-04-30 EDT			5-day change	1st Jan Change
1.34 ^USD	-1.09%		+0.75%	+97.06%

04-18	Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine	MT
04-18	Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101	04-18
Top Midday Gainers	03-28
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28
Imunon, Inc. Files Ind Application to Begin Human Testing of Imnn-101	03-13
IMUNON Names Executive Chairman as Temporary Head Following Resignation of CEO Corinne Le Goff	03-13
Imunon, Inc. Announces Executive Changes	03-12
Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024	03-12
Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer	12-11
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer	11-14
IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer	23-10-18
Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board	23-10-06
Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board	23-08-14
Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv	23-08-07
Imunon Opening New Manufacturing Facility in Alabama to Support Production of Vaccine Formulation Components	23-06-27
IMUNON, Inc. Unveils New Manufacturing Capabilities at Huntsville's HudsonAlpha Biotech Campus	23-06-27
Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors	23-06-14
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Imunon, Inc.

Equities

IMNN

US15117N6022

Other languages

Filters